-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Verastem (VSTM) PT Lowered to $16 at RBC Capital
-
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
-
Verastem Oncology (VSTM) Prices 7.18M Share and Warrant Offering at $9.75/sh
-
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
-
Verastem Oncology (VSTM) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Verastem Oncology to Participate in Upcoming Investor Conferences
-
UPDATE: RBC Capital Starts Verastem (VSTM) at Outperform
-
Pre-Open Movers 05/16: (BOOT) (ABAX) (M) Higher; (VSTM) (SRAX) (ABR) Lower (more...)
-
Notable Analyst Rating Changes 07/29: (TTM) (DHI) (WCRX) Upgraded; (MSFT) (TROW) (RVBD) Downgraded

